 |
PDBsum entry 2nz6
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
|
PDB id:
|
 |
|
 |
| Name: |
 |
Hydrolase
|
 |
|
Title:
|
 |
Crystal structure of the ptprj inactivating mutant c1239s
|
|
Structure:
|
 |
Receptor-type tyrosine-protein phosphatase eta. Chain: a. Fragment: tyrosine-protein phosphatase. Synonym: protein-tyrosine phosphatase eta, r-ptp-eta, hptp eta, protein- tyrosine phosphatase receptor type j, density-enhanced phosphatase 1, dep-1, cd148 antigen. Engineered: yes. Mutation: yes
|
|
Source:
|
 |
Homo sapiens. Human. Organism_taxid: 9606. Gene: ptprj. Expressed in: escherichia coli bl21(de3). Expression_system_taxid: 469008.
|
|
Biol. unit:
|
 |
Trimer (from
)
|
|
Resolution:
|
 |
|
2.30Å
|
R-factor:
|
0.184
|
R-free:
|
0.228
|
|
|
Authors:
|
 |
E.Ugochukwu,A.Barr,P.Savitsky,A.C.W.Pike,G.Bunkoczi,M.Sundstrom, J.Weigelt,C.H.Arrowsmith,A.Edwards,F.Von Delft,S.Knapp,Structural Genomics Consortium (Sgc)
|
Key ref:
|
 |
A.J.Barr
et al.
(2009).
Large-scale structural analysis of the classical human protein tyrosine phosphatome.
Cell,
136,
352-363.
PubMed id:
DOI:
|
 |
|
Date:
|
 |
|
22-Nov-06
|
Release date:
|
12-Dec-06
|
|
|
|
|
|
PROCHECK
|
|
|
|
|
Headers
|
 |
|
|
References
|
|
|
|
|
|
|
Q12913
(PTPRJ_HUMAN) -
Receptor-type tyrosine-protein phosphatase eta from Homo sapiens
|
|
|
|
Seq: Struc:
|
 |
 |
 |
1337 a.a.
296 a.a.*
|
|
|
|
|
|
|
|
|
 |
 |
|
|
Key: |
 |
PfamA domain |
 |
 |
 |
Secondary structure |
 |
 |
CATH domain |
 |
|
*
PDB and UniProt seqs differ
at 26 residue positions (black
crosses)
|
|
|
|
|
 |
|
|
 |
 |
 |
 |
Enzyme class:
|
 |
E.C.3.1.3.48
- protein-tyrosine-phosphatase.
|
|
 |
 |
 |
 |
 |
Reaction:
|
 |
O-phospho-L-tyrosyl-[protein] + H2O = L-tyrosyl-[protein] + phosphate
|
 |
 |
 |
 |
 |
O-phospho-L-tyrosyl-[protein]
|
+
|
H2O
|
=
|
L-tyrosyl-[protein]
|
+
|
phosphate
Bound ligand (Het Group name = )
corresponds exactly
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Molecule diagrams generated from .mol files obtained from the
KEGG ftp site
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
|
| |
|
DOI no:
|
Cell
136:352-363
(2009)
|
|
PubMed id:
|
|
|
|
|
| |
|
Large-scale structural analysis of the classical human protein tyrosine phosphatome.
|
|
A.J.Barr,
E.Ugochukwu,
W.H.Lee,
O.N.King,
P.Filippakopoulos,
I.Alfano,
P.Savitsky,
N.A.Burgess-Brown,
S.Müller,
S.Knapp.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
Protein tyrosine phosphatases (PTPs) play a critical role in regulating cellular
functions by selectively dephosphorylating their substrates. Here we present 22
human PTP crystal structures that, together with prior structural knowledge,
enable a comprehensive analysis of the classical PTP family. Despite their
largely conserved fold, surface properties of PTPs are strikingly diverse. A
potential secondary substrate-binding pocket is frequently found in
phosphatases, and this has implications for both substrate recognition and
development of selective inhibitors. Structural comparison identified four
diverse catalytic loop (WPD) conformations and suggested a mechanism for loop
closure. Enzymatic assays revealed vast differences in PTP catalytic activity
and identified PTPD1, PTPD2, and HDPTP as catalytically inert protein
phosphatases. We propose a "head-to-toe" dimerization model for RPTPgamma/zeta
that is distinct from the "inhibitory wedge" model and that provides a molecular
basis for inhibitory regulation. This phosphatome resource gives an expanded
insight into intrafamily PTP diversity, catalytic activity, substrate
recognition, and autoregulatory self-association.
|
|
|
|
|
| |
Selected figure(s)
|
|
|
| |
 |
 |
|
 |
|
 |
Figure 3.
Figure 3. Novel Conformations and Movement of the Catalytic
(WPD) Loop (A) WPD loop conformations are shown by a PTP
representative of each state: closed (blue, PTP1B, PDB: 1SUG);
open (yellow, PTP1B, PDB: 2HNP); and atypical (magenta, GLEPP1,
PDB: 2GJT; STEP, PDB: 2BIJ; Lyp, PDB: 2P6X). The intermediate
WPD loop conformation of PCPTP1 (PDB: 2A8B) is not shown for
clarity. Other PTP structures are shown with a thin transparent
line tracing the backbone and are colored according to
conformation. (B) Superimposition of the structure of
STEP-C/S in complex with pY (PDB: 2CJZ; gray) and the apo STEP
(PDB: 2BIJ; light green) showing that the WPD loop conformation
does not change on substrate binding (pTyr, orange). The
catalytic water molecule (Wa) corresponding to that found in
closed structures is shown. (C) Superimposition of the
structure of STEP-C/S in complex with pY (PDB: 2CJZ; green) and
PTP1B with the insulin receptor peptide (PDB: 1G1H; red). The
conserved water molecule found in closed structures is shown:
PTP1B (1SUG, yellow); GLEPP1 (2G59, orange); HePTP (2A3K,
black), DEP1 (2NZ6, magenta). The arrow indicates the position
of the displaced water molecule in STEP-C/S structure.
|
 |
Figure 4.
Figure 4. Secondary Substrate-Binding Pockets (A) Two
extreme conformations of the second-site loop are shown (orange)
from RPTPγ (extended helix) and HEPTP (closed in conformation).
The catalytic cysteine is shown in a space-filling CPK
representation, and loops are colored as follows: WPD (magenta),
β5/β6 loop (green), and gateway (red). The dually pTyr
phosphorylated insulin receptor peptide (from PDB: 1G1H) is
shown superimposed (for reference only) to indicate the position
of the secondary substrate-binding pocket. The positions of
Arg24 and gateway residues Met258 and Gly259 of PTP1B are shown
in an enlarged view. (B) Surface topology and electrostatic
charge for the active site (pY), gateway region, and secondary
pocket (2pY) are shown for each of the five categories with the
dually pTyr phosphorylated insulin receptor peptide
superimposed. (C) Representative second-site loop
conformations are shown for each category (see also Supplemental
Data). Category I: SHP2, BDP1, LYP; Category II: IA2, IA2β;
Category III: LAR, RPTPσ; Category IV: PTPH1, MEG1, PTPD2,
CD45; Category V: STEP, HEPTP, PCPTP1.
|
 |
|
|
|
| |
The above figures are
reprinted
from an Open Access publication published by Cell Press:
Cell
(2009,
136,
352-363)
copyright 2009.
|
|
| |
Figures were
selected
by the author.
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
E.Ferrari,
M.Tinti,
S.Costa,
S.Corallino,
A.P.Nardozza,
A.Chatraryamontri,
A.Ceol,
G.Cesareni,
and
L.Castagnoli
(2011).
Identification of new substrates of the protein-tyrosine phosphatase PTP1B by Bayesian integration of proteome evidence.
|
| |
J Biol Chem,
286,
4173-4185.
|
 |
|
|
|
|
 |
H.Hashemi,
M.Hurley,
A.Gibson,
V.Panova,
V.Tchetchelnitski,
A.Barr,
and
A.W.Stoker
(2011).
Receptor tyrosine phosphatase PTPγ is a regulator of spinal cord neurogenesis.
|
| |
Mol Cell Neurosci,
46,
469-482.
|
 |
|
|
|
|
 |
S.G.Julien,
N.Dubé,
S.Hardy,
and
M.L.Tremblay
(2011).
Inside the human cancer tyrosine phosphatome.
|
| |
Nat Rev Cancer,
11,
35-49.
|
 |
|
|
|
|
 |
S.J.Davis,
and
P.A.van der Merwe
(2011).
Lck and the nature of the T cell receptor trigger.
|
| |
Trends Immunol,
32,
1-5.
|
 |
|
|
|
|
 |
S.Liu,
Z.Yu,
X.Yu,
S.X.Huang,
Y.Luo,
L.Wu,
W.Shen,
Z.Yang,
L.Wang,
A.M.Gunawan,
R.J.Chan,
B.Shen,
and
Z.Y.Zhang
(2011).
SHP2 is a target of the immunosuppressant tautomycetin.
|
| |
Chem Biol,
18,
101-110.
|
 |
|
|
|
|
 |
V.V.Vintonyak,
H.Waldmann,
and
D.Rauh
(2011).
Using small molecules to target protein phosphatases.
|
| |
Bioorg Med Chem,
19,
2145-2155.
|
 |
|
|
|
|
 |
E.Zeqiraj,
and
D.M.van Aalten
(2010).
Pseudokinases-remnants of evolution or key allosteric regulators?
|
| |
Curr Opin Struct Biol,
20,
772-781.
|
 |
|
|
|
|
 |
K.Mahajan,
and
N.P.Mahajan
(2010).
Shepherding AKT and androgen receptor by Ack1 tyrosine kinase.
|
| |
J Cell Physiol,
224,
327-333.
|
 |
|
|
|
|
 |
R.A.Fernandes,
C.Yu,
A.M.Carmo,
E.J.Evans,
P.A.van der Merwe,
and
S.J.Davis
(2010).
What controls T cell receptor phosphorylation?
|
| |
Cell,
142,
668-669.
|
 |
|
|
|
|
 |
S.Bouyain,
and
D.J.Watkins
(2010).
The protein tyrosine phosphatases PTPRZ and PTPRG bind to distinct members of the contactin family of neural recognition molecules.
|
| |
Proc Natl Acad Sci U S A,
107,
2443-2448.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
S.Bouyain,
and
D.J.Watkins
(2010).
Identification of tyrosine phosphatase ligands for contactin cell adhesion molecules.
|
| |
Commun Integr Biol,
3,
284-286.
|
 |
|
|
|
|
 |
S.M.Burden-Gulley,
T.J.Gates,
A.M.Burgoyne,
J.L.Cutter,
D.T.Lodowski,
S.Robinson,
A.E.Sloan,
R.H.Miller,
J.P.Basilion,
and
S.M.Brady-Kalnay
(2010).
A novel molecular diagnostic of glioblastomas: detection of an extracellular fragment of protein tyrosine phosphatase mu.
|
| |
Neoplasia,
12,
305-316.
|
 |
|
|
|
|
 |
X.Zhang,
Y.He,
S.Liu,
Z.Yu,
Z.X.Jiang,
Z.Yang,
Y.Dong,
S.C.Nabinger,
L.Wu,
A.M.Gunawan,
L.Wang,
R.J.Chan,
and
Z.Y.Zhang
(2010).
Salicylic acid based small molecule inhibitor for the oncogenic Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2).
|
| |
J Med Chem,
53,
2482-2493.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
A.E.Hower,
P.J.Beltran,
and
J.L.Bixby
(2009).
Dimerization of tyrosine phosphatase PTPRO decreases its activity and ability to inactivate TrkC.
|
| |
J Neurochem,
110,
1635-1647.
|
 |
|
|
|
|
 |
A.Edwards
(2009).
Large-scale structural biology of the human proteome.
|
| |
Annu Rev Biochem,
78,
541-568.
|
 |
|
|
|
|
 |
D.Krishnamurthy,
and
A.M.Barrios
(2009).
Profiling protein tyrosine phosphatase activity with mechanistic probes.
|
| |
Curr Opin Chem Biol,
13,
375-381.
|
 |
|
|
|
|
 |
D.Vidović,
and
S.C.Schürer
(2009).
Knowledge-based characterization of similarity relationships in the human protein-tyrosine phosphatase family for rational inhibitor design.
|
| |
J Med Chem,
52,
6649-6659.
|
 |
|
|
|
|
 |
F.Sacco,
M.Tinti,
A.Palma,
E.Ferrari,
A.P.Nardozza,
R.Hooft van Huijsduijnen,
T.Takahashi,
L.Castagnoli,
and
G.Cesareni
(2009).
Tumor suppressor density-enhanced phosphatase-1 (DEP-1) inhibits the RAS pathway by direct dephosphorylation of ERK1/2 kinases.
|
| |
J Biol Chem,
284,
22048-22058.
|
 |
|
|
|
|
 |
J.Weigelt
(2009).
The case for open-access chemical biology. A strategy for pre-competitive medicinal chemistry to promote drug discovery.
|
| |
EMBO Rep,
10,
941-945.
|
 |
|
|
|
|
 |
K.Hofmeyer,
and
J.E.Treisman
(2009).
The receptor protein tyrosine phosphatase LAR promotes R7 photoreceptor axon targeting by a phosphatase-independent signaling mechanism.
|
| |
Proc Natl Acad Sci U S A,
106,
19399-19404.
|
 |
|
|
|
|
 |
M.C.Gingras,
Y.L.Zhang,
D.Kharitidi,
A.J.Barr,
S.Knapp,
M.L.Tremblay,
and
A.Pause
(2009).
HD-PTP is a catalytically inactive tyrosine phosphatase due to a conserved divergence in its phosphatase domain.
|
| |
PLoS ONE,
4,
e5105.
|
 |
|
|
|
|
 |
N.Krishnan,
D.G.Jeong,
S.K.Jung,
S.E.Ryu,
A.Xiao,
C.D.Allis,
S.J.Kim,
and
N.K.Tonks
(2009).
Dephosphorylation of the C-terminal Tyrosyl Residue of the DNA Damage-related Histone H2A.X Is Mediated by the Protein Phosphatase Eyes Absent.
|
| |
J Biol Chem,
284,
16066-16070.
|
 |
|
|
|
|
 |
S.J.Tsai,
U.Sen,
L.Zhao,
W.B.Greenleaf,
J.Dasgupta,
E.Fiorillo,
V.Orrú,
N.Bottini,
and
X.S.Chen
(2009).
Crystal structure of the human lymphoid tyrosine phosphatase catalytic domain: insights into redox regulation .
|
| |
Biochemistry,
48,
4838-4845.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
S.Wu,
S.Vossius,
S.Rahmouni,
A.V.Miletic,
T.Vang,
J.Vazquez-Rodriguez,
F.Cerignoli,
Y.Arimura,
S.Williams,
T.Hayes,
M.Moutschen,
S.Vasile,
M.Pellecchia,
T.Mustelin,
and
L.Tautz
(2009).
Multidentate small-molecule inhibitors of vaccinia H1-related (VHR) phosphatase decrease proliferation of cervix cancer cells.
|
| |
J Med Chem,
52,
6716-6723.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
Y.Tong,
P.K.Hota,
J.Y.Penachioni,
M.B.Hamaneh,
S.Kim,
R.S.Alviani,
L.Shen,
H.He,
W.Tempel,
L.Tamagnone,
H.W.Park,
and
M.Buck
(2009).
Structure and function of the intracellular region of the plexin-b1 transmembrane receptor.
|
| |
J Biol Chem,
284,
35962-35972.
|
 |
|
PDB code:
|
 |
|
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
Where a reference describes a PDB structure, the PDB
codes are
shown on the right.
|
');
}
}
 |